Shanghai, China --- The confirmatory clinical trial on the safety and efficacy of thoracic surgery was successfully completed on January 16, 2022 with Toumai^® Laparoscopic Surgical Robot (Toumai^®) independently developed by Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot®). The trial was jointly conducted by Professor Qingquan Luo of Shanghai Chest Hospital, Professor Bentong Yu from the First Affiliated Hospital of Nanchang University, Professor Jinzhi Xu from the Fourth Hospital of Harbin Medical University and Professor Yunjiu Gou from Gansu Provincial Hospital. So far, Toumai^® has become the first Chinese-developed laparoscopic surgical robot for confirmatory clinical trial case enrollment completed in the field of thoracic surgery.

 Toumai^® provides the operators with 3D HD images beyond the direct vision effect and accurate as well as stable operation experience, perfect integration of doctors with the robot, and gives full play to the advantages of robot-assisted surgery. Compared with the traditional thoracoscopic surgery, the endoscope of Toumai^® can be separately controlled by the surgeon and provide a comfortable angle and field of view. The stable robotic arm and exquisite structure high-performance surgical instruments can fully dissociate the pulmonary vessels, bronchus and other related tissues, and the switchover of robotic arms can achieve the tissue tracting and fine operation at the same time, thus improving the surgical efficiency.

Mr. Yu Liu, Chief Commercial Officer of MicroPort® MedBot®, said: "Thanks to the thoracic surgery experts for their enthusiasm and expectation for the development of Chinese-developed surgical robots. They have successfully completed the confirmatory clinical trial cases of thoracic surgery with Toumai^®. The excellent performance of Toumai^® has fully proved that the Chinese-developed surgical robots is not only competent for all difficult pelvic surgeries, but also can assist the doctors in completing complex operations in the thoracic area. With the joint promotion and strong support of clinical experts, and the increasing popularity of clinical application of Chinese-developed surgical robots, MicroPort® MedBot® will endeavor to create more possibilities for surgical diagnosis and treatment, bring more choices to surgeons and patients."